Dr. Reddy’s Laboratories announces the launch of Fenofibrate Tablets USP, in the U.S. Market
Hyderabad: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® (fenofibrate) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Tricor® brand and generic had U.S. sales of approximately $90 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.
Dr. Reddy’s Fenofibrate Tablets USP, are available in 54 mg dose in bottle count size of 90 and 160 mg dose in bottle count sizes of 90 and 500.
Tricor® is a trademark of AbbVie Inc.
*IQVIA Retail and Non-Retail MAT January 2020.